Is Balaxi Pharma overvalued or undervalued?

As of 17 November 2025, Balaxi Pharma's valuation grade has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 13.68, an EV to EBIT of 10.81, and a Price to Book Value of 0.83. These ratios suggest that Balaxi Pharma is trading at a discount compared to its earnings and book value, which is favorable for potential investors.
In comparison to its peers, Balaxi Pharma's valuation metrics are significantly more appealing. For instance, Bajaj Finance has a PE ratio of 34.85, while Life Insurance stands at 11.33, both of which highlight Balaxi's competitive positioning within the pharmaceuticals and biotechnology sector. Additionally, Balaxi's PEG ratio is notably low at 0.00, further reinforcing its undervaluation. Despite recent stock performance lagging behind the Sensex, with a year-to-date decline of 50.32% compared to the Sensex's gain of 10.02%, the current valuation metrics suggest that Balaxi Pharma presents a compelling investment opportunity.